+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

IASLC African Impact Grant

International Association for the Study of Lung Cancer

Building on the success of the inaugural International Association for the Study of Lung Cancer (IASLC) Pan-Africa Conference on Lung Cancer, the IASLC Board of Directors has allocated funds to support innovative lung cancer work in Africa. These funds are intended to support the work of the IASLC and the IASLC’s Strategic Plan, with the ultimate goal of conquering thoracic cancers worldwide in the 21st century.

Funding Priority

The goal of these grants is to support an effort to gather data on the epidemiology of lung cancer in Africa and encourage advocacy, public engagement, and policy initiatives. Sustainability and Impact will be major criteria for selection.

All projects must support at least one of the following topics:

(1) Lung Cancer Epidemiology (in a country, countries or region, such as West, East, North or Southern Africa) / Lung Cancer Detection, in particular distinguishing lung cancer from tuberculosis (TB) or

(2) Advocacy, Public Awareness and/or Policy for Lung Cancer

Applications that involve more than one specialty and more than one country are strongly encouraged.

Grant Timeline

Application Portal Opens: September 10, 2025
LOI Submission Deadline: October 31, 2025 at 12:00PM (noon) MST
Applicants Notified of LOI Decision: November 25, 2025
Invited RFP Submission Deadline: December 31, 2026 at 12:00PM (noon) MST
Notification of Award: By February 15, 2026
Project Start Date: By March 25, 2026

AI Based Application Success Predictor

1. Clear Focus on Lung / Thoracic Malignancies (Not Generic Cancer)

Since IASLC is entirely devoted to thoracic cancers, proposals must directly target lung cancer (or thoracic tumors) — whether basic biology, translational, clinical, epidemiology, prevention, or health-services research.
Generic oncology proposals (non-lung) usually don’t fit their mandate.

2. Matching the Right Grant Mechanism to Career Stage & Project Scope

Successful applications are well-aligned:

Early-career / post-doc ⇒ Young Investigator Grant or Fellowship

Mid-career investigators seeking transition to independence ⇒ Career Advancement Grant

Groups seeking translational impact or large-scale research ⇒ Team-Science / Translational Grants

Regional / population-based studies, esp. in under-served regions ⇒ Impact / Regional Grants

Predictor: A tight match between career stage + project maturity + grant type is critical. Mis-matching lowers competitiveness.

3. Strong Scientific / Clinical Rationale + High Relevance to Lung Cancer

Funded projects often:

Address unmet needs (therapy resistance, early detection, biomarkers, new targets)

Propose novel mechanisms or translational ideas

Have clinical or patient-impact relevance: mortality, early diagnosis, improved care, therapy outcomes

Predictor: Proposals combining scientific rigor with clinical relevance (from lab to bedside) rank top.

4. Feasibility: Defined Aims, Responsible Scope, Realistic Timeline & Budget

Successful submissions have:

Clear, focused aims (often 2–4) with defined milestones

Realistic budget (e.g. IASLC Young Investigator Grant is US $50,000 for one year)

Plan for deliverables: data, pilot results, translational endpoints, etc.

Proper use of funds (e.g. no oversized overheads, no unrealistic equipment purchases on small grants)

Predictor: Feasible, well-structured studies --- especially under smaller grants — are more likely to be funded.

5. Preliminary Data (especially for translational or higher-level grants)

While small fellowships/grants may accept exploratory proposals, larger or more translational grants tend to favor preliminary evidence:

Preclinical data (cell lines, animal models)

Feasibility data for biomarkers, diagnostics, datasets

Evidence of access to clinical samples, patient cohorts, or collaborator networks

Predictor: Demonstrated feasibility via pilot data significantly boosts the chance of funding.

6. Collaboration, Multidisciplinary Team & International/Global Perspective

IASLC values:

Multidisciplinary teams (basic science + clinical oncology + pathology + statistics)

Multi-centre collaborations, especially for large or translational projects

Global/regional relevance — epidemiology, population-based studies, resource-limited settings (e.g., African Impact Grants)

Predictor: Proposals with strong collaborations and global reach get higher priority.

7. Clear Translational or Public Health Impact

Funded projects often aim toward:

Early detection or screening strategies

Biomarkers for diagnosis/therapy response

Improved treatment protocols, personalized therapy

Understanding population differences / disparities in lung cancer

Public health or policy-relevant data (especially in impact/regional grants)

Predictor: Potential for real-world impact — patient outcome, access, global health — is strongly favored.

8. Investigator Track Record (for mid-career / advanced grants) or Strong Mentorship & Support (for early-career)

Mid-career / independent-level: prior relevant publications, evidence of capability, previous grant history

Early-career / fellows: good mentorship plan, institution support, appropriate training plan

Predictor: Reviewers weigh investigator credibility or mentorship plan heavily depending on grant type.

9. Ethical, Realistic & Region-Appropriate Design (for Global / Impact Grants)

Especially for grants focused on epidemiology, Africa, or resource-limited settings:

Proper study design considering local healthcare infrastructure

Realistic recruitment plans, statistical power, sustainability

Advocacy, policy or public-health integration as part of impact

Predictor: Realism and context awareness are critical to succeed in global/regional grant calls.

10. Commitment to Dissemination, Data Sharing, & Long-Term Lung Cancer Research Ecosystem

IASLC is not just a funder — it fosters a global community:

Publication in their journal(s)

Presentation at IASLC conferences (e.g., WCLC)

Participation in collaborative networks or consortia

Proposals that foresee sharing data, engaging the broader community, or building infrastructure are favorably viewed.

🎯 What This Means If You're Writing a Grant to IASLC

Make sure your research is squarely about lung or thoracic cancer (not general oncology).

Choose the correct grant track — early-career, fellowship, translational, or impact — based on your experience and project maturity.

Formulate a focused, feasible project with clear aims, realistic timeline, and appropriate budget.

Provide preliminary data or compelling rationale showing feasibility, especially for translational or clinical ideas.

Build a multidisciplinary, collaborative team, ideally with international or multi-centre partners for broader impact.

Emphasize translational potential or public-health significance — e.g., early detection, biomarker development, access in resource-poor regions.

Ensure ethical design, realistic recruitment/implementation plan (especially for global/regional proposals).

Outline a plan for data sharing, dissemination, and long-term research continuity.

If early career — ensure mentorship & institutional support; if mid-career — highlight prior work and capability to lead.

Specialties

Cancer

Pulmonology

Eligibility Requirements

IASLC African Impact Grants are open to candidates currently living and conducting research in Africa. At the time of application, the applicant must meet all these requirements:

Multiple Principal Investigators (MPI) are allowed, but there should be a designated corresponding PI who will be responsible for reporting on the project’s progress.

The designated corresponding PI may be affiliated with only one proposal.

All investigators must be affiliated with a healthcare institution

PIs and Co-PIs must be members of the IASLC (if applicants are not current members, one-year membership may be provided at the discretion of the review committee).

Grant applications should include an inventory/statistics about the institutions where principal investigators practice and its workforce, including:

Number of lung cancer cases seen in a year

Number of medical oncologists, thoracic surgeons, clinical oncologists, pulmonologists, pathologists and other health care personnel involved in lung cancer treatment or research at your institution

Sponsor Details

Sponsor Institute/Organizations: International Association for the Study of Lung Cancer

Sponsor Type: Corporate/Non-Profit

Address: 1775 N. Sherman Street, Suite 1600, Denver, CO 80203-4317

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity